RxDoctor Payments Data

William Martinez, PA

Medical · Los Angeles, CANPI 1124161120

Payments from drug & device makers

$564in general payments, 2019–2025

Across 30 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$121
  • Bayer$114
  • Novo Nordisk$74
  • AbbVie$69
  • Redhill Biopharma Inc.$48
  • Sumitomo Pharma America, Inc.$43
  • plus $96 from 3 others

What the payments were for

  • Food & beverage$564100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$564 in reported general payments places this provider in the 50th percentile of 2,087 medical providers in California.

See all medical providers in California

Medicare billing

Part B allowed, 2024
$71,653
Medicare patients
243
Services billed
2,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide233$259,884
JardianceEmpagliflozin343$247,595
JanuviaSitagliptin Phosphate223$157,299
JanumetSitagliptin Phos/Metformin Hcl197$153,889
EntrestoSacubitril/Valsartan174$151,468
FarxigaDapagliflozin Propanediol196$145,896
EliquisApixaban124$87,209
GemtesaVibegron134$81,658
Tresiba Flextouch U-200Insulin Degludec90$62,310
TrulicityDulaglutide52$49,043
CreonLipase/Protease/Amylase32$42,084
XifaxanRifaximin12$36,814
DapagliflozinDapagliflozin Propanediol51$33,560
MyrbetriqMirabegron44$27,477
XareltoRivaroxaban26$26,457

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$74$281,986250 claims
AstraZenecaFarxiga, Bevespi Aerosphere$33$158,869224 claims
NovartisEntresto$121$151,468174 claims
PfizerEliquis$35$87,209124 claims
Sumitomo Pharma America, Inc.Gemtesa$43$81,658134 claims
AbbVieCreon, Linzess, Lumigan$69$66,13881 claims
Lilly USA, LLCTrulicity$28$49,04352 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,087 medical providers in California.

Other medical in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →